An experimental antiviral compound developed by BioCryst Pharmaceuticals and the U.S. Army Medical Research Institute of Infectious Diseases provided complete protection in monkeys against Marburg virus and Ebola, two highly virulent pathogens with no effective treatments.
Academic research institutions play a crucial role in the drug development process, especially on the preclinical research and drug discovery side, as Big Pharma companies are increasingly cutting back their R&D spending. While many of the research institutions featured here are still doing plenty of basic science research, interest seems to be growing among these universities in repurposing existing drugs or those that never made it into the marketplace because of safety issues.
We've taken a look at some of the best research institutions in the U.S. and ranked by them by their level of funding from the National Institutes of Health, the largest funder of biomedical research in the world. The report highlights some of the important drug discovery research coming out of these universities that FierceBiotech Research covered in 2013, but it is by no means a comprehensive look at every research initiative at these institutions.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
A new discovery that explains how the body's immune system makes a potent antibody that blocks HIV infection may be an important step toward developing a vaccine against the virus.
Announced earlier this week, President Barack Obama's proposed budget for 2015 includes $30.4 billion for the National Institutes of Health, a slight increase of $211 million over this fiscal year's budget.
Oregon Health & Science University is opening a new Center for Embryonic Cell and Gene Therapy to study experimental treatments for Parkinson's disease, multiple sclerosis and a range of other conditions caused by diseased or injured cells in the human body.
International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
Researchers think they've discovered why previous efforts at targeting the enzyme LTA4 hydrolase, a key player in the body's inflammatory response, have failed and produced a new molecule that may prove more successful.
A supplement that activates a protein involved in metabolic balance showed an extension in lifespan and improvement in the overall health of mice, according to a new study.
From Our Sister Sites
Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA's concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.
Fresh off positive results for its late-stage lung drug, InterMune has attracted some M&A interest from a flock of pharmaceutical companies, according to Reuters, sending the biotech's shares up roughly 12% on Friday.